Loading
PRECEDE is a very large international study following people whose genes or family history put them at high risk of pancreatic cancer, with yearly scans and stored blood samples, to find out how to catch the cancer early enough to cure it; it is still enrolling towards 20,000 participants.
PRECEDE (the Pancreatic Cancer Early Detection Consortium) is a prospective observational cohort registered by Arbor Research Collaborative for Health and run across more than 40 academic centres. It enrols people at high risk of pancreatic ductal adenocarcinoma, including carriers of germline pathogenic variants, members of familial pancreatic cancer kindreds, people with pancreatic cysts and cohorts with new-onset diabetes, in defined cohorts with protocol-driven surveillance imaging and longitudinal biospecimen collection. The primary outcome is the development of pancreatic ductal adenocarcinoma; the consortium's stated aim is to raise five-year survival by detecting the disease at a curable stage.
The registry lists an estimated 20,000 participants with completion in 2030 and no results. With the older CAPS programme it defines high-risk surveillance on the corpus's pancreatic cancer page.
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
The stage shift the pancreatic cancer page quotes (about three in four surveillance-detected cancers at stage I) and the strongest argument for offering surveillance to every germline carrier found by universal testing, which the NHS does not yet do outside research.
PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.
The rulebook behind the CAPS cohorts and the UK EUROPAC programme; it is also the reason surveillance for carriers is not yet a routine NHS service, because the consortium itself asked for it to stay within research until benefit was shown.
The first long-term evidence that surveillance in high-risk people finds operable cancers, and the source of the imaging features that trigger surgery in the CAPS recommendations.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
Shares Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium, Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium, Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Shares CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5), Familial pancreatic cancer and inherited risk (who qualifies for surveillance), High-risk pancreatic surveillance (CAPS / PRECEDE), Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.